Shaun G. Goodman

St. Michael's Hospital
Edmonton, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 371 publications

Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial.

Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial.

Journal: European journal of preventive cardiology

Published: July 18, 2026

Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial.

Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial.

Journal: American heart journal

Published: July 02, 2026

Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial.

Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial.

Journal: Circulation

Published: May 18, 2026

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study.

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study.

Journal: Blood

Published: February 24, 2026

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Journal: Blood

Published: February 24, 2026

Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.

Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.

Journal: American heart journal

Published: February 13, 2026

Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.

Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.

Journal: American heart journal

Published: February 13, 2026

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.

Journal: JAMA cardiology

Published: February 04, 2026

The Effect of Restrictive vs Liberal Blood Transfusion Strategy on Subsequent Myocardial Infarction Type.

The Effect of Restrictive vs Liberal Blood Transfusion Strategy on Subsequent Myocardial Infarction Type.

Journal: JACC. Advances

Published: January 05, 2026

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.

Journal: Circulation

Published: December 01, 2025

A comprehensive set of per-protocol analyses of the myocardial ischemia and transfusion (MINT) trial.

A comprehensive set of per-protocol analyses of the myocardial ischemia and transfusion (MINT) trial.

Journal: American heart journal

Published: November 06, 2025

Effect of age on restrictive and liberal transfusion outcomes in patients with anemia and myocardial infarction.

Effect of age on restrictive and liberal transfusion outcomes in patients with anemia and myocardial infarction.

Journal: American heart journal

Published: October 17, 2025

Showing 1-12 of 371

Last Updated: 09/26/2026